Danaher (DHR) dropped 13% despite reporting second quarter earnings and revenue above expectations. The life sciences equipment manufacturer lowered full year core revenue growth guidance to between 3% and 4%. It also forecast third quarter core revenue growth between 2% and 3%. The weaker outlook overshadowed the earnings beat.